BioSpace News Archive

BioStem Technologies Inc. announced today that it plans to release its fourth quarter 2023 financial results post-market Monday, April 01, 2024.

Lisata Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to LSTA1, the Company’s lead product candidate, for the treatment of osteosarcoma, a rare cancer that can develop in children, adolescents and young adults.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announces a poster presentation at the American Chemistry Society (ACS) Spring 2024 Meeting, held March 17-21, 2024, in New Orleans, Louisiana.

Human Immunology Biosciences (HI-Bio™) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for felzartamab for the treatment of antibody-mediated rejection (AMR) in kidney transplant recipients.

Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced four upcoming presentations and posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

TriSalus Life Sciences® Inc. (Nasdaq: TLSI) announced today that the Company will present data from recent research findings at the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, to be held March 23-28, 2024, in Salt Lake City, Utah.

Elixir Medical today announced it has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its DynamX ® BTK System.

Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine),

Public Health Vaccines, LLC (PHV) has started its Phase 1 clinical trial (NCT06265012) to evaluate the safety and immunogenicity of the company’s single-dose vaccine (PHV01) against Marburg virus - a hemorrhagic fever virus of the Filoviridae family that causes Marburg virus disease, a rare but severe hemorrhagic fever that affects people and non-human primates and has a case fatality rate of up to 88%.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.